Tenofovir vs entecavir

Common Questions and Answers about Tenofovir vs entecavir

truvada

Avatar m tn For the first 39 months of use of <span style = 'background-color: #dae8f4'>entecavir</span>/<span style = 'background-color: #dae8f4'>tenofovir</span> there is not significant difference in HCC development for <span style = 'background-color: #dae8f4'>tenofovir</span> vs entecavir for non-cirrhotic...as probably expected since pre-malignancy was probably already developed in those HCC cases. For Cirrhotic tenofovir maybe seems to be just slightly better option. For non-cirrhotic usage of interferon in the past reduced chances of HCC by 29% in this study.
Avatar f tn another important test is precore/bcp mutants test, adefovir, lamivudine and entecavir mutants test and genotype test if you have no precore/bcp mutants your hbeag positive status will have 16% hbv clearance with the use of tenofovir plus entecavir, 24% tenofovir plus entecavir plus interferon.
Avatar f tn guideline has made treatment failure with <span style = 'background-color: #dae8f4'>entecavir</span> and <span style = 'background-color: #dae8f4'>tenofovir</span> monotherapy when hbvdna has not reached und by 1 year, your doctor has made a mistake and you might be exposed to etv resistance.
Avatar m tn Hi all, A report about <span style = 'background-color: #dae8f4'>tenofovir</span>. Should HBVers change to <span style = 'background-color: #dae8f4'>entecavir</span> and if yes what is the long term safety for entecavir ? Please adivse Link : http://www.hivandhepatitis.
17174583 tn?1456156546 I don't know if <span style = 'background-color: #dae8f4'>entecavir</span> is causing those, but it's possible. My mother couldn't stand entecavir, she started shaking. Doctors told her it was impossible, but I could see her shaking two hours after taking it. Switched to tenofovir and it never happenned anyome. Ask your doctor to change to tenofovir, give it a try.
Avatar m tn HepNet.Greece cohort. Papatheodoridis GV1, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. Author information Abstract Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine.
Avatar m tn 5 people experienced serious adverse events, including 3 ALT flares during the <span style = 'background-color: #dae8f4'>entecavir</span> monotherapy phase. Neutropenia (0% <span style = 'background-color: #dae8f4'>vs</span> 23%) and thrombocytopenia (0% vs 8%) were significantly more common in the add-on group compared with the monotherapy group; no one in either arm developed anemia. 2 people developed severe neutropenia while on pegylated interferon.
Avatar m tn potent antivirals like <span style = 'background-color: #dae8f4'>tenofovir</span> and <span style = 'background-color: #dae8f4'>entecavir</span> can make response despite only 3 years of hbvdna suppression and high hbsag.
Avatar m tn //www.medhelp.org/posts/Hepatitis-B/gilead-trl7-agonist-and-others-already-marketed/show/1685432#post_8125376 http://www.medhelp.org/posts/Hepatitis-B/gilead-trl7-agonist-and-others-already-marketed/show/1685432#post_8132560 http://www.medhelp.
Avatar f tn My new GI said she will try to switch me from <span style = 'background-color: #dae8f4'>entecavir</span> and either put me on <span style = 'background-color: #dae8f4'>tenofovir</span> or Peginterferon. I ask for a combo and she told me that tenofovir and Peginterferon does the same thing. Is that even true?
Avatar m tn Patients were treated with NAs therapy (lamivudine, adefovir, telbivudine, <span style = 'background-color: #dae8f4'>entecavir</span> and <span style = 'background-color: #dae8f4'>tenofovir</span>) for at least 2 years. qHBsAg was performed every 6 months. Results Our results showed a significantly greater qHBsAg decline after 2 years in patients treated with tenofovir (0.45 logIU/ml) than in patients treated with telbivudine (0.12 logIU/ml; P < 0.001).
Avatar m tn Well you can try <span style = 'background-color: #dae8f4'>tenofovir</span> and see how you tolerate it. It supposed to be slightly better then entecavir - meaning more potent. If you have issues with TDF (Viread) then stop and try Baraclude. They are very comparable group of drugs. With entecavir yes it is better to take it on an empty stomach. What I do with Baraclude is I take it at night 4 -5 hours after a meal, and then I eat 8 hours after. I find it best to keep me functional. p.s. you don't mention about your labs btw.
Avatar m tn Thirdly, my doctor says it's pretty much a flip of the coin to decide whether to go with Baraclude(<span style = 'background-color: #dae8f4'>entecavir</span>) or Viread(<span style = 'background-color: #dae8f4'>tenofovir</span>). There seems to be very little data about the success rate of either. Can anyone please help me to decide which route to take? For example, comparison of side-effects, success rate(i guess that means sero-conversion) in asians, etc. And finally, how much of a difference would it make if I start treatment now or in, say, 6 months?
Avatar m tn Patients were treated with NAs therapy (lamivudine, adefovir, telbivudine, <span style = 'background-color: #dae8f4'>entecavir</span> and <span style = 'background-color: #dae8f4'>tenofovir</span>) for at least 2 years. qHBsAg was performed every 6 months. Results Our results showed a significantly greater qHBsAg decline after 2 years in patients treated with tenofovir (0.45 logIU/ml) than in patients treated with telbivudine (0.12 logIU/ml; P < 0.001).
Avatar m tn As you can see, guidelines do change and evolve over the years. As the long term effectiveness and safety of <span style = 'background-color: #dae8f4'>tenofovir</span>/entecavir are established, there will be a tendency to treat whenever there is an elevated viral load. Fibroscan score and qHbsAg will also become more important factors in determining when and how to treat. What is clear is that there is a huge unmet demand for more treatment drugs and a cure. Just my opinion.
948882 tn?1270557407 htm International patients have a link as well. U.S. CLINICAL TRIALS FOR CHRONIC HBV NEW! - <span style = 'background-color: #dae8f4'>tenofovir</span> Alone <span style = 'background-color: #dae8f4'>vs</span>. <span style = 'background-color: #dae8f4'>tenofovir</span> with Emtricitabine for CHB Test whether the combination of two medications, tenofovir and emtricitabine, are safer and more effective for treating CHB than tenofovir alone. Contact: Patient Recruitment and Public Liaison Office (800) 411-1222 or ***@**** (Study ID# 07-DK-0207 / Identifier - NCT00524173). NEW!
Avatar m tn TAF <span style = 'background-color: #dae8f4'>vs</span>. TDF for the Treatment of HBeAg (-) CHB – U.S. and International Evaluate the safety and efficacy of tenofovir alafenamide (TAF) compared to that of tenofovir disproxil fumarate (TDF) in treatment naïve and experienced adults with CHB as determined by the achievement of HBV DNA <29 IU/mL at Week 48.
Avatar m tn i am checking all pros and cons about <span style = 'background-color: #dae8f4'>entecavir</span>/<span style = 'background-color: #dae8f4'>tenofovir</span> combo <span style = 'background-color: #dae8f4'>vs</span> <span style = 'background-color: #dae8f4'>entecavir</span> mono for me and in general for all. i am probably in cirrhosis or early cirrhosis and doctor put me in etecavir mono because of tenofovir kidney problems and possible discontinuation of tx but: checking tenofovir trials on hbv only (no hiv coinfection) kidney problems are in less than 1% patients and i haven't found tx discontinuation because of kidney problems.
Avatar m tn Notably, just 2% of combination <span style = 'background-color: #dae8f4'>entecavir</span>/<span style = 'background-color: #dae8f4'>tenofovir</span> recipients and 3% of <span style = 'background-color: #dae8f4'>entecavir</span> monotherapy recipients experienced serum creatinine increases (≥ 0.3 mg/dL), a possible indicator of kidney impairment, which is a potential toxicity of tenofovir. http://www.hivandhepatitis.
Avatar m tn HBeAg seroconversion was also less likely in the <span style = 'background-color: #dae8f4'>entecavir</span>/<span style = 'background-color: #dae8f4'>tenofovir</span> arm (22% <span style = 'background-color: #dae8f4'>vs</span> 33%). Virological breakthrough occurred in 4% of <span style = 'background-color: #dae8f4'>entecavir</span>/tenofovir recipients and 1% of entecavir monotherapy recipients. However, no entecavir or tenofovir drug resistance mutations were detected in either arm Maybe Potent A + Potent B is not twice the potency and barrier to resistance. I don't know.
Avatar n tn at this point the best choice would be tenofovir which is much cheaper and much potent with no resistance detected until now, also nitazoxanide should work preventing resistance but i don t suggest that for this purpose since we only have in vitro studies and no in vivo trials about prevention of resistance tenofovir has also a generic called tenvir (about 99usd), tenofovir is also sold at about 10usd or less per bottles in poor asian countries where the generic tenvir is taking all the market
Avatar f tn The preferred treatment for <span style = 'background-color: #dae8f4'>tenofovir</span> resistance is switch to or add <span style = 'background-color: #dae8f4'>entecavir</span>. However, the alternate treatment is switch to Truvada according to Prof Anna Lok).
Avatar n tn so your friend should have start with tenofovir from the begining as guidelines say now luckily at the end of all this mess on 2008/2009 guidelines only tenofovir can be used as first line therapy and entecavir only in naive patients.
Avatar m tn 25% <span style = 'background-color: #dae8f4'>vs</span>. 54%; P = 0.063 and 24% <span style = 'background-color: #dae8f4'>vs</span>. 57%; P = 0.036, respectively). At 3 years, 9% of the HBeAg-positive and 14% of the HBeAg-negative patients became HBsAg-negative. Prolonged consolidation therapy increased the likelihood of HBsAg loss. Two cirrhotic patients developed hepatic decompensation but both recovered. Conclusions After nucleos(t)ide analogue discontinuation, relapse was common in patients with chronic hepatitis B.
948882 tn?1270557407 Medication (see also Medication, below) Currently, interferon alfa (IFN-a), lamivudine, telbivudine, adefovir, <span style = 'background-color: #dae8f4'>entecavir</span>, and <span style = 'background-color: #dae8f4'>tenofovir</span> are the main treatment drugs approved globally, although ongoing trials are investigating new types of medications, such as tenofovir disoproxil in combination with emtricitabine, clevudine (l-FMAU), and therapeutic vaccines. It appears that lamivudine and telbivudine are not recommended as first-line agents in the treatment of hepatitis B disease.
Avatar m tn These compounds are other nuceloside analogs, variants, as so many exist, that act principally like <span style = 'background-color: #dae8f4'>tenofovir</span> or <span style = 'background-color: #dae8f4'>entecavir</span>. The chance for any one of those to achieve practical standing at this time of historical development is extremely small. The only drug currently in advanced development with a very realistic chance to join the established very selected antiviral HBV drug family is the following.
9624973 tn?1413019730 there are critical decisions that has to be make ...